Digital Solutions Advance Your mRNA Manufacturing Workflow

Some experts predict that digital technologies will increasingly impact the biomanufacturing industry, leading to further advancements in therapeutic production. The question remains: is biopharma prepared to embrace these changes?

Implementing advanced automation, developing smart plants, and transitioning to paperless manufacturing can significantly improve digital maturity in drug manufacturing processes. These improvements can reduce costs, save time, and mitigate risks. For emerging mRNA-based drugs, which often require small, intensified batches, using automated, digital data management rather than paper-based recordkeeping can offer even more competitive advantages. This article explores the advantages of paperless manufacturing for small and emerging companies, the importance of incorporating a digital strategy early in the manufacturing process, and how digital solutions for mRNA manufacturing can help small batch manufacturers produce these essential medicines more effectively.